fda bpc-157 compounding category 2 list 1 vs. Category 2. The FDA's peptide update, explained. Category peptides are on the FDA's “difficult to compound” list, which effectively blocks licensed pharmacies from producing them. Category 1 means The FDA just announced that
The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) FDA Advisers Vote to Ease Restrictions on BPC 157, TB 500, and Other Novel Peptides Glitchwire Updated 2026 FDA Category 2 peptide list As the science and regulations continue to develop, it's important to work with providers who stay informed and prioritize safe, medically guided protocols. At FDA Peptide Update: Category 2 Removals Explained Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8 6 to recommend adding BPC 157 to the 503A Bulks List for use in compounding for
Pay in 4 interest-free payments of $7.21 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4

